Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
(4) - EconoTimes)
DUBLIN, Ireland, April 04, 2018 -- Horizon Pharma plc (NASDAQ:HZNP) today announced that the compensation committee of its board of directors approved the grant on Apr. 1, 2018 of inducement restricted stock units for an aggregate of 55,395 ordinary shares to 21 new employees.
Some of the restricted stock units vest over four years, with 1/4 of the shares vesting on each anniversary of the applicable vesting commencement date, and some of the restricted stock units vest over three years, with 1/3 of the shares vesting on each anniversary of the applicable vesting commencement date. All awards are subject to the new employee's continued service relationship with the Company. Each restricted stock unit also is subject to the terms and conditions of the Company's 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Tina Ventura
Senior Vice President, Investor Relations
[email protected]
Ruth Venning
Executive Director, Investor Relations
[email protected]
U.S. Media Contact:
Geoffrey Curtis
Senior Vice President, Corporate Affairs and Chief Communications Officer
[email protected]
Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]
